Preclinical studies have suggested combinations of mTOR and MEK inhibitors in KRAS mutant lung cancers [120] but these attempts have proven challenging due to adverse events such as diarrhea, skin rash and fatigue [121]. Here, MAP2K7 is linked to lung cancer.